# A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®

> **NCT01705236** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 87 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis RRMS

## Interventions

- **DRUG:** Fingolimod

## Key facts

- **NCT ID:** NCT01705236
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-20
- **Primary completion:** 2019-02-18
- **Final completion:** 2019-02-18
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2020-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01705236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01705236, "A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01705236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*